HSK 39775
Alternative Names: HSK-39775Latest Information Update: 22 Jun 2024
At a glance
- Originator Haisco Pharmaceutical Group
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 21 Mar 2024 Preclinical trials in Solid tumours (Late-stage disease) in China (PO) prior to March 2024.
- 07 Mar 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Monotherapy, Second-line therapy or greater) in China (PO) (NCT06314373)